Determination of low molecular weight heparin in clinical laboratory.
The applicability was investigated of automated spectrophotometric heparin assays and three clotting assays for determination of two low molecular weight (LMW) heparin fractions: Org 10172 and DxN10 and two infractionated commercially available heparins. The relative activity of the two commercially available heparins was similar in the anti-Xa assay, in the anti-IIa assay and in 3 clotting assays. The LMW heparins showed markedly different relative activity in all 5 assays. The activities of those heparin preparations relative to the standard heparin were compared in the 5 assays, but standardization against a standard heparin preparation appeared impossible. Methods of heparin determination can be used to monitor treatment with a heparin preparation only if the same preparation is used as a reference substance.
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004151:Dipeptides; D006025:Glycosaminoglycans / Q000032:analysis / Q000097:blood; D006493:Heparin / Q000032:analysis* / Q000097:blood; D006496:Heparinoids / Q000032:analysis; D006497:Heparan Sulfate; D006801:Humans; D008970:Molecular Weight; D009842:Oligopeptides; D010314:Partial Thromboplastin Time; D012016:Reference Values; D013053:Spectrophotometry
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D004151:Dipeptides; D006025:Glycosaminoglycans; D006493:Heparin; D006496:Heparinoids; D006497:Heparan Sulfate; D009842:Oligopeptides; C015608:benzoyl-Ile-Glu-Gly-Arg-p-nitroanilide; C021129:S 2238; C035838:danaparoid